<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> may be a common phenotype increasing risk for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We assessed the prevalence and characteristics of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> among population-based samples of 3,224 white subjects attending Framingham Offspring Study (FOS) exam 5 (1991-1995) and 1,081 non-Hispanic white and 1,656 Mexican-American subjects attending the San Antonio Heart Study (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SAHS</z:e>) phase II follow-up exam (1992-1996) </plain></SENT>
<SENT sid="2" pm="."><plain>Subjects were approximately 50% women, aged 30-79 years, without <z:mp ids='MP_0002055'>diabetes</z:mp>, and classified with the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> according to criteria for <z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>, and <z:hpo ids='HP_0000822'>hypertension</z:hpo> proposed by the Third Report of the National Cholesterol Education Program's Adult Treatment Panel (ATP III) or the World Health Organization (WHO) </plain></SENT>
<SENT sid="3" pm="."><plain>We used regression models to estimate rates across ethnic groups and to assess the association of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> with <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and predicted 10-year <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e> (CHD) risk </plain></SENT>
<SENT sid="4" pm="."><plain>Among FOS white subjects, the age- and sex-adjusted prevalence of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> was 24% by both ATP III and WHO criteria; among <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SAHS</z:e> non-Hispanic white subjects, 23 and 21%, respectively; and among <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SAHS</z:e> Mexican-American subjects, 31 and 30% </plain></SENT>
<SENT sid="5" pm="."><plain>Rates were highest among Mexican-American women (ATP III, 33%) and lowest among white women (21%) </plain></SENT>
<SENT sid="6" pm="."><plain>Subjects with the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> by ATP III criteria had higher age-, sex-, and ethnicity-adjusted levels of fasting insulin (11.3 micro U/ml), homeostasis model assessment of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> (2.7), and predicted CHD risk (11.8%) than those without the syndrome (5.9 micro U/ml, 1.3, and 6.4%, respectively; <z:hpo ids='HP_0000001'>all</z:hpo> P = 0.0001); differences were similar using WHO criteria </plain></SENT>
<SENT sid="7" pm="."><plain>We conclude that the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> typically affects 20-30% of middle-aged adults in the U.S </plain></SENT>
<SENT sid="8" pm="."><plain>By any criteria, subjects with the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> are more insulin resistant and at increased predicted risk for CHD versus those without the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
</text></document>